Related references
Note: Only part of the references are listed.Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
A. Jayk Bernal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
William A. Fischer et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Omicron variant and booster COVID-19 vaccines
Talha Khan Burki
LANCET RESPIRATORY MEDICINE (2022)
Making Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial
Kristian Thorlund et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2022)
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Jienchi Dorward et al.
BRITISH JOURNAL OF GENERAL PRACTICE (2022)
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 x 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
David M. Lowe et al.
PLOS MEDICINE (2022)
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
Robert M. Cox et al.
NATURE MICROBIOLOGY (2021)
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
Wendy P. Painter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies
Silke Gastine et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Angela Wahl et al.
NATURE (2021)
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
Rana Abdelnabi et al.
EBIOMEDICINE (2021)
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
Kyle Rosenke et al.
NATURE COMMUNICATIONS (2021)
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Saye H. Khoo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Molnupiravir: coding for catastrophe
Brandon Malone et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
Gail Hayward et al.
BMJ OPEN (2021)
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Christopher C. Butler et al.
LANCET RESPIRATORY MEDICINE (2021)
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
Mart Toots et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
β-D-N4-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome
Nadya Urakova et al.
JOURNAL OF VIROLOGY (2018)
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Janet Woodcock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach
Cedric Laouenan et al.
BMC MEDICAL RESEARCH METHODOLOGY (2013)
Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial
Paul Little et al.
LANCET INFECTIOUS DISEASES (2013)
Are racial and ethnic minorities less willing to participate in health research?
D Wendler et al.
PLOS MEDICINE (2006)
Information leaflet and antibiotic prescribing strategies for acute lower respiratory tract infection - A randomized controlled trial
P Little et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Pragmatic clinical trials
H MacPherson
COMPLEMENTARY THERAPIES IN MEDICINE (2004)